Samuel Saks

Samuel Saks, M.D., joined Jazz Pharmaceuticals at its inception. From 2001 until he joined Jazz Pharmaceuticals, Dr. Saks was company group chairman of ALZA Corporation and member of the Johnson & Johnson Pharmaceutical Operating Committee. From 1992 until 2001, Dr. Saks held executive positions at ALZA, including Group Vice President, ALZA Pharmaceuticals, where he was responsible for clinical, regulatory and commercial activities. Prior to joining ALZA, Dr. Saks held clinical research and development management positions with Schering-Plough, Xoma and Genentech.

Dr. Saks received his Bachelor’s degree in biology and his medical degree from the University of Illinois. He completed his residency in internal medicine at Texas Southwestern, and his fellowship in oncology at the University of California - San Francisco, and is Board certified in both specialties. Dr. Saks is a director of Trubion Pharmaceuticals and a scientific advisor to ArQule Pharmaceuticals, Inc., CMEA Ventures and ProQuest Investments.

Premier Sponsor:
Ernst & Young